Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@onco_park Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1211752034942078977.png) @onco_park Byung-June Park

Byung-June Park posts on X about satisfactory, $4528t, jj, rates the most. They currently have XXXXX followers and XXX posts still getting attention that total X engagements in the last XX hours.

### Engagements: X [#](/creator/twitter::1211752034942078977/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211752034942078977/c:line/m:interactions.svg)

- X Week XX -XX%
- X Month XXXXX +244%
- X Months XXXXX -XX%
- X Year XXXXXXX +62%

### Mentions: X [#](/creator/twitter::1211752034942078977/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211752034942078977/c:line/m:posts_active.svg)

- X Week X -XX%
- X Month XX -XXXX%
- X Months XX -XX%
- X Year XXX +24%

### Followers: XXXXX [#](/creator/twitter::1211752034942078977/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211752034942078977/c:line/m:followers.svg)

- X Week XXXXX +0.04%
- X Month XXXXX +0.21%
- X Months XXXXX +3.10%
- X Year XXXXX +42%

### CreatorRank: undefined [#](/creator/twitter::1211752034942078977/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211752034942078977/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1211752034942078977/influence)
---

**Social topic influence**
[satisfactory](/topic/satisfactory), [$4528t](/topic/$4528t), [jj](/topic/jj), [rates](/topic/rates)
### Top Social Posts [#](/creator/twitter::1211752034942078977/posts)
---
Top posts by engagements in the last XX hours

"Q224_Genmab's Oncology X. Genmab's R&D strategy will focus on advancing mid-to-late-stage projects like EPKINLY Tivdak acasunlimab and Rina-S. While early-stage investments have reached a satisfactory level future efforts will be more moderate prioritizing pivotal trials and potential registrations for key assets. X. At #ESMO24 updated data on Rina-S will be presented showing significant activity across various FR expression levels compared to Elehere. Genmab plans to initiate a Phase X trial for 2L PROC by the end of 2024. The company attributes Rina-S's superior safety profile to its"  
[X Link](https://x.com/onco_park/status/1821951433668735007) [@onco_park](/creator/x/onco_park) 2024-08-09T16:47Z 2361 followers, 1960 engagements


"Ono Pharmaceutical has inked two key deals with LigaChem Biosciences. First Ono secured worldwide exclusive rights to LCB97 LCB's L1CAM-targeting ADC for solid tumors. Second the companies agreed to collaborate on developing new ADC candidates using LCB's ConjuAll ADC platform"  
[X Link](https://x.com/onco_park/status/1844304885627453842) [@onco_park](/creator/x/onco_park) 2024-10-10T09:12Z 2361 followers, XXX engagements


"J&J has decided not to exercise its license option for HexaBody-CD38. Genmab will discontinue further clinical development of HexaBody-CD38 maintaining its previously stated focus on advancing late-stage assets Rina-S and acasunlimab. HexaBody-CD38 showed slightly higher ORR VGPR and CR rates compared to daratumumab though the differences were not substantial"  
[X Link](https://x.com/onco_park/status/1899107328022188100) [@onco_park](/creator/x/onco_park) 2025-03-10T14:37Z 2361 followers, 4105 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@onco_park Avatar @onco_park Byung-June Park

Byung-June Park posts on X about satisfactory, $4528t, jj, rates the most. They currently have XXXXX followers and XXX posts still getting attention that total X engagements in the last XX hours.

Engagements: X #

Engagements Line Chart

  • X Week XX -XX%
  • X Month XXXXX +244%
  • X Months XXXXX -XX%
  • X Year XXXXXXX +62%

Mentions: X #

Mentions Line Chart

  • X Week X -XX%
  • X Month XX -XXXX%
  • X Months XX -XX%
  • X Year XXX +24%

Followers: XXXXX #

Followers Line Chart

  • X Week XXXXX +0.04%
  • X Month XXXXX +0.21%
  • X Months XXXXX +3.10%
  • X Year XXXXX +42%

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #


Social topic influence satisfactory, $4528t, jj, rates

Top Social Posts #


Top posts by engagements in the last XX hours

"Q224_Genmab's Oncology X. Genmab's R&D strategy will focus on advancing mid-to-late-stage projects like EPKINLY Tivdak acasunlimab and Rina-S. While early-stage investments have reached a satisfactory level future efforts will be more moderate prioritizing pivotal trials and potential registrations for key assets. X. At #ESMO24 updated data on Rina-S will be presented showing significant activity across various FR expression levels compared to Elehere. Genmab plans to initiate a Phase X trial for 2L PROC by the end of 2024. The company attributes Rina-S's superior safety profile to its"
X Link @onco_park 2024-08-09T16:47Z 2361 followers, 1960 engagements

"Ono Pharmaceutical has inked two key deals with LigaChem Biosciences. First Ono secured worldwide exclusive rights to LCB97 LCB's L1CAM-targeting ADC for solid tumors. Second the companies agreed to collaborate on developing new ADC candidates using LCB's ConjuAll ADC platform"
X Link @onco_park 2024-10-10T09:12Z 2361 followers, XXX engagements

"J&J has decided not to exercise its license option for HexaBody-CD38. Genmab will discontinue further clinical development of HexaBody-CD38 maintaining its previously stated focus on advancing late-stage assets Rina-S and acasunlimab. HexaBody-CD38 showed slightly higher ORR VGPR and CR rates compared to daratumumab though the differences were not substantial"
X Link @onco_park 2025-03-10T14:37Z 2361 followers, 4105 engagements

creator/x::onco_park
/creator/x::onco_park